Sugi Predict

Sugi Predict / Compounds / SCHEMBL713634

SCHEMBL713634

SCHEMBL713634

Nc1nc(=O)c([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PNP P00491 8/20 0.50
▸ LMNA P02545 4/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ MTOR P42345 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ GMNN O75496 2/20 0.40
▸ NFKB1 P19838 2/20 0.40
▸ BLM P54132 2/20 0.40
▸ PMP22 Q01453 2/20 0.40
▸ UMPS P11172 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ MDM2 Q00987 1/20 0.40
▸ NCOA1 Q15788 1/20 0.40
▸ NCOA3 Q9Y6Q9 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ DNMT1 P26358 1/20 0.40
▸ THPO P40225 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14066117 1.00 PNP (0.50) PNPLMNASMN1; SMN2MTORALDH1A1
SCHEMBL10081193 1.00 PNP (0.50) PNPLMNASMN1; SMN2MTORALDH1A1
SCHEMBL19442443 1.00 PNP (0.50) PNPLMNASMN1; SMN2MTORALDH1A1
SCHEMBL14365990 1.00 PNP (0.50) PNPLMNASMN1; SMN2MTORALDH1A1
SCHEMBL902517 1.00 PNP (0.50) PNPLMNASMN1; SMN2MTORALDH1A1
SCHEMBL22990557 0.83 PNP (0.42) PNPLMNASMN1; SMN2GMNNNFKB1
SCHEMBL25843590 0.83 PNP (0.42) PNPLMNASMN1; SMN2GMNNNFKB1
SCHEMBL24400617 0.81 PNP (0.41) PNPLMNASMN1; SMN2GMNNNFKB1
SCHEMBL2778662 0.81 PNP (0.47) PNPLMNASMN1; SMN2MTORALDH1A1
SCHEMBL4588335 0.81 PNP (0.47) PNPLMNASMN1; SMN2MTORALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4092472-A 2,4-Dichloro-5-(β-D-ribofuranosyl) pyrimidines and substituted derivatives UNIVERSITY OF UTAH (US) 1978-05-30 — — US claimed
US-20140187434-A1 Nucleic Acid Labeling Compounds AFFYMETRIX, INC. (US) 2014-07-03 — — US disclosed
US-8497064-B2 Nucleic acid labelling compounds AFFYMETRIX, INC. (US) 2013-07-30 — — US disclosed
US-20120053336-A1 Nucleic Acid Labelling Compounds AFFYMETRIX, INC. (US) 2012-03-01 — — US disclosed
US-8076072-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2011-12-13 — — US disclosed
US-8026057-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2011-09-27 — — US disclosed
US-20110082289-A1 Nucleic Acid Labeling Compounds AFFYMETRIC, INC. (US) 2011-04-07 — — US disclosed
US-7468243-B2 Nucleotide sequence labelling compoumd four use as tool in genetic engineering AFFYMETRIX, INC. (US) 2008-12-23 — — US disclosed
US-20080287667-A1 Nucleic Acid Labeling Compounds AFFYMETRIX, INC. (US) 2008-11-20 — — US disclosed
US-7291463-B2 Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis AFFYMETRIX, INC. (US) 2007-11-06 — — US disclosed
US-20050003496-A1 Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis AFFYMETRIX, INC. (US) 2005-01-06 — — US disclosed
US-20040210045-A1 Nucleic acid labeling compounds MCGALL GLENN (US) 2004-10-21 — — US disclosed
WO-2004052907-A1 NUCLEIC ACID LABELING COMPOUNDS AFFYMETRIX, INC. (US) 2004-06-24 — — WO disclosed
US-20040101892-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2004-05-27 — — US disclosed
EP-1385829-A2 NUCLEIC ACID LABELING COMPOUNDS Affymetrix, Inc. (US) 2004-02-04 — — EP disclosed
US-20030180757-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2003-09-25 — — US disclosed
US-20020182625-A1 Nucleotide sequence labelling compoumd four use as tool in genetic engineering AFFYMETRIX, INC. 2002-12-05 — — US disclosed
US-20020165372-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2002-11-07 — — US disclosed
WO-2002072779-A2 NUCLEIC ACID LABELING COMPOUNDS AFFYMETRIX, INC. (US) 2002-09-19 — — WO disclosed
US-4092472-A 2,4-Dichloro-5-(β-D-ribofuranosyl) pyrimidines and substituted derivatives UNIVERSITY OF UTAH (US) 1978-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082289-A1 Nucleic Acid Labeling Compounds RNGTT, DUT, FBL PNP 25/4885LMNA 582/4885SMN1; SMN2 1952/4885
US-20080287667-A1 Nucleic Acid Labeling Compounds RNGTT, DUT, FBL PNP 32/4885LMNA 560/4885SMN1; SMN2 2189/4885
US-20030180757-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL PNP 32/4885LMNA 547/4885SMN1; SMN2 1926/4885
US-20040101892-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL PNP 32/4885LMNA 547/4885SMN1; SMN2 1926/4885
US-20120053336-A1 Nucleic Acid Labelling Compounds RNGTT, DUT, FBL PNP 24/4885LMNA 673/4885SMN1; SMN2 1923/4885
US-20020165372-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL PNP 32/4885LMNA 547/4885SMN1; SMN2 1926/4885
US-20050003496-A1 Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis DUT, PCNA, BCDIN3D PNP 96/4885LMNA 695/4885SMN1; SMN2 2978/4885
US-20040210045-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL PNP 32/4885LMNA 547/4885SMN1; SMN2 1926/4885
US-20020182625-A1 Nucleotide sequence labelling compoumd four use as tool in genetic engineering RNGTT, POLM, RNMT PNP 38/4885LMNA 1886/4885SMN1; SMN2 2965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.